ZEVRA THERAPEUTICS, INC.

Zevra Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing treatments for rare diseases. The company operates through its Ligand Activated Technology platform and maintains a pipeline spanning multiple therapeutic areas. Its marketed products include AZSTARYS for attention deficit and hyperactivity disorder in patients aged six and older, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. The company is advancing several clinical-stage candidates, including KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol in Phase 3 development for vascular Ehlers-Danlos syndrome.

Zevra maintains collaborative partnerships to expand its product portfolio. The company holds a collaboration and licensing agreement with Commave Therapeutics SA for product candidates combining SDX and d-methylphenidate, and licensing agreements with Acer and Relief Therapeutics for OLPRUVA commercialization rights. The company was formerly known as KemPharm, Inc. before rebranding in February 2023.

Headquartered in Celebration, Florida, Zevra operates with 59 full-time employees and is incorporated in Delaware. The company is listed on Nasdaq. As a commercial-stage entity with both marketed products and an active clinical pipeline, Zevra generates revenue primarily from product sales and partnership arrangements.